Immunocore Holdings plc Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Immunocore Holdings plc (IMCR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $25.33 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Immunocore Holdings plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $22.76, a 6.65% increase year-over-year.
- Immunocore Holdings plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $21.34, a 14.67% increase year-over-year.
- Immunocore Holdings plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $18.61.
- Immunocore Holdings plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $19.82, a 7.19% increase from fiscal 2024.
- Immunocore Holdings plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $18.49, a 11.66% decline from fiscal 2023.
- Immunocore Holdings plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $20.93, a 6.14% increase from fiscal 2022.
- Immunocore Holdings plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $19.72, a 15.93% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.33 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $22.76 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $19.82 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $19.73 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $20.26 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $21.34 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $18.49 10-K · filed 2025-02-26 | |||
| 2024-09-30 | $19.06 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $18.90 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $18.61 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $20.93 10-K · filed 2024-02-28 | |||
| 2022-12-31 | $19.72 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $17.01 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |